• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    K

    KMU Institute of Medical Sciences

    院校
    565论文总数
    7,399引用总数

    KMU Institute of Medical and dental Sciences (Urdu: جامعہ طبی خیبر- کالج علوم کوہاٹ, Pashto: د خیبر طبی علومو پوهنتون کوهاټ), in Kohat, Khyber Pakhtunkhwa, Pakistan, is a public sector medical college, established in April 2006.KMU-IMS/IDS, the constituent body of KMU, enrolls students in a five-year programme leading to the Bachelor of Medicine and Bachelor of Surgery (MBBS) degrees, and also in the four-year programme leading to Bachelor of Dental Surgery (BDS).It is a public sector medical institution approved by the Pakistan Medical and Dental Council. Each year 100 students are enrolled, on basis of their performance in ETEA test, in MBBS and 50 are enrolled in BDS.It is affiliated with Khyber Medical University, Peshawar.

    论文量&引用量时间轴

    机构学者

    论文(565)

    年份
    起
    –
    止
    排序
    1Effect of Influenza Vaccination on Major Cardiovascular Events and Mortality: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Muhammad Waqar Shahid, Abdullah Hameed, Ayesha Naseem, Fatima Sajjad, Moin Haider Shah, Hamna Khan, Afridi Jahangir Khan, Muhammad Talha Usman, Yasar Ullah, Hiba Abeer, Malaika Shakeel, Arsalan Khan,

    Cardiovascular disease remains the leading global cause of mortality despite advances in preventive therapies. Influenza infection is increasingly recognized as a trigger for acute cardiovascular events, prompting interest in influenza vaccination as a potential cardioprotective intervention in high-risk patients. We aimed to conduct a systematic review and meta-analysis to evaluate the effect of influenza vaccination on cardiovascular outcomes in adults with established cardiovascular disease. PubMed, Embase, and Cochrane databases were systematically searched using relevant keywords from inception until October 2025. Seven studies were included after the final screening. Outcomes were reported as all cause mortality, myocardial infarction, major adverse cardiovascular events and heart failure related hospitalization. Interstudy heterogeneity was assessed using I² and X² statistics. Statistical calculations were performed using Review Manager 5.4.1, with a p-value of < 0.05 indicating statistical significance. Seven randomized controlled trials including 12,224 participants were analyzed. Influenza vaccination significantly reduced major adverse cardiovascular events and cardiovascular mortality. A borderline reduction was observed for myocardial infarction and all-cause mortality. No significant differences were found for stroke, coronary revascularization, or heart failure-related hospitalization. Heterogeneity was low for most primary outcomes. The routine use of influenza vaccination as an effective adjunctive strategy in secondary cardiovascular prevention is supported by the fact that it significantly lowers cardiovascular mortality and major cardiovascular events in patients with established heart disease.

    2026Critical pathways in cardiology(2026)
    引用
    AI阅读
    加入学术空间
    2Impact of Lipid-Based Nutritional Supplementation on Cardio Metabolic Risk Factors in Underweight Pre-Eclamptic Primigravidas: A Randomized Controlled Trial
    Hafsa Zafar,Murad A. Mubaraki, Mashal Zafar,Nabila Sher,Rubina Nazli,Kalsoom Tariq, Hashim Khan,Ijaz Ahmad, Fozia

    Pre-eclampsia is a major cause of maternal and fetal complications in Pakistan, particularly among primigravidas, where poor nutritional status further increases risk. Emerging evidence suggests that underweight pre-eclamptic women may have distinct cardio metabolic adaptations, higher susceptibility to adverse pregnancy outcomes, and increased long-term cardiovascular risk. Lipid-based nutritional supplementation provides essential energy and micronutrients and may help improve maternal metabolic status and pregnancy outcomes in pre-eclamptic women. To determine the effect of lipid-based micronutrient supplementation on lipid profile, Insulin resistance and blood pressure in underweight pre-eclamptic primigravidas at delivery, six months and twelve months postnatal. An open label randomized controlled trial was undertaken to explore the effects of supplementation on the cardio metabolic risk factors in the tertiary care hospitals of KPK, Pakistan. A total of sixty primigravidas were randomized equally into two groups; Group A: control group and Group B; supplement group. At delivery, 26 and 28 participants in Groups A and B, respectively and at 6 and 12 months, 23 and 25 participants were analyzed. In addition to their prescribed antenatal treatment of preeclampsia and IFA (60 mg iron and 400ug FA) daily, the Group B also received one 75gm of lipid-based nutrition supplement (LNS) sachet (MAAMTA) daily from their first antenatal visit after enrollment till one year postnatally. The IFA was stopped 6 weeks after delivery. There was no discernable difference among the baseline cardio-metabolic parameters like insulin, glucose HOMA-IR of two groups at delivery. Also, the difference in BP (systolic) was non-significant while BP (diastolic) was decreased in group B (p = 0.025). Similarly, at delivery the significant declined were observed in triglyceride (TGs) levels with LNS supplementation (p = 0.007), Total cholesterol (p = 0.01), LDL (p = 0.02) and VLDL (p = 0.005). At 6 months follow-up systolic (p = 0.002) and diastolic blood pressure (p = 0.013) were decreased significantly in group B also a significant decline in TGs (p = 0.05), cholesterol (p < 0.001), LDL (p < 0.001) and VLDL levels (p = 0.04) observed in group B. A significant decrease was seen in cholesterol levels (p < 0.001) and LDL levels (p < 0.001) in group B at 12 months postnatal. This study concludes that long term LNS supplementation can cause a decrease in cholesterol, TGs, LDL and VLDL in underweight pre-eclamptic primigravidas and thus may contribute to a more favorable cardio metabolic risk profile. ClinicalTrials.gov Identifier: ISRCTN 15485068. Registered on April 21, 2018: https://doi.org/10.1186/ISRCTN15485068.

    2026BMC Pregnancy and Childbirth(2026)
    引用
    AI阅读
    加入学术空间
    3Enhanced Recovery after Surgery Versus Conventional Care in Elderly Patients Undergoing Transvaginal Pelvic Floor Reconstruction: A Systematic Review and Meta-Analysis
    Aqsa Khanzada, Syeda Vilay Zehra Rizvi, Farah Hadi, Benish Khan, Fatima Sajjad, Fazia Khattak, F. N. U. Fahad, Fatima Abid, Fatima Yousaf,Kainat Sheraz, F. N. U. Laiba, Laila Mehsood,

    Pelvic organ prolapse is a common condition in older women requiring surgical correction. The benefits of Enhanced Recovery After Surgery (ERAS) have been demonstrated in gynecological procedures, but there are still few data on its use in older patients (aged 60 years and above) undergoing transvaginal pelvic floor reconstruction. This study evaluates the effectiveness and safety of ERAS compared with conventional perioperative care, specifically in this older population. A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Embase, and Cochrane databases were searched for randomized and observational studies comparing ERAS with conventional care in older patients undergoing transvaginal pelvic floor reconstruction. Outcomes assessed were time to first intestinal exhaust, ambulation, urinary catheterization duration, hospital stay, operative time, bleeding volume, 30-day readmission, and reoperation rates. Data extraction and quality assessment were performed independently, and pooled analyses were conducted using a random-effects model. Nine studies involving 1,585 patients were included. ERAS significantly reduced time to first intestinal exhaust, ambulation, urinary catheter removal, and postoperative length of stay compared with conventional care. No significant differences were observed in operative duration, intraoperative bleeding, 30-day readmission, or reoperation rates. For older patients undergoing transvaginal pelvic floor reconstruction, ERAS enhances postoperative recovery without sacrificing safety. The need for multicenter randomized studies and standardized protocols remains despite encouraging findings.

    2026International Urogynecology Journal(2026)
    引用
    AI阅读
    加入学术空间
    4Sex, Racial/Ethnic, and Regional Disparities in Mortality Involving Both Cardiac Arrest and Type 2 Diabetes Mellitus among U.S. Adults, 1999–2020
    Asma Chaudhary,Aizaz Anwar Khalid, Fawaz-ur-Rehman,Rubbia Sabir, Anas M Din Bashir,Rumman Javed, Kashaf Fatima, Muhammad Younas,Aisha Chaudhary,Yasar Sattar

    Type 2 Diabetes mellitus (T2DM) and cardiac arrest (CA) drive significant mortality and healthcare costs in the U.S., yet national trends and disparities remain unclear. This study aims to evaluate national trends in mortality involving concurrent T2DM and CA among the U.S. adult population. Using Centers for Disease Control and Prevention Wide Ranging Online Data for Epidemiologic Research (CDC WONDER) database, we analyzed deaths among U.S. adults aged ≥ 25 (1999–2020) from T2DM (ICD-10: E11) and CA (ICD-10: I46), calculating crude and age-adjusted mortality rates (AAMR) per 100,000 and estimating annual percent change (APC) via Joinpoint regression stratified by sex, race/ethnicity, age and geography. Between 1999 and 2020, 258,675 deaths involving both T2DM and CA occurred. AAMRs increased from 1999 to 2014 (APC 2.72) and surged through 2020 (APC 9.55). Mortality was higher in men than in women (AAMR 6.75 vs. 4.36). Marked racial and ethnic disparities were observed, with the highest mortality rates among Hispanic (AAMR 10.92) and non-Hispanic (NH) American Indian/Alaska Native populations (10.16), while NH Whites had the lowest rates (4.35). The sharpest increases in AAMR were observed in younger adults. Geographically, the Western region and metropolitan areas exhibited the highest mortality burden. At the state level, California had the highest AAMR, whereas Maryland had the lowest. Mortality related to coexisting T2DM and CA increased substantially in the United States from 1999 to 2020, with an accelerated rise after 2014, particularly among younger adults and ethnic minorities. These findings highlight an urgent need for targeted cardiovascular preventive strategies in these high-risk cohorts. For T2DM and CA, mortality rate nearly tripled from 1999 to 2020, with a sharp acceleration beginning in 2014. Men and Hispanic populations faced the highest mortality rates. Western and metropolitan areas exhibited highest mortality rates. The steepest rise in AAMR occurred in adults aged 35–44.

    2026Journal of Racial and Ethnic Health Disparities(2026)
    引用
    AI阅读
    加入学术空间
    5Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies.
    Nazish Munawar, Aakash Mahato,Anurag Rawat, Fahad Shaukat Gill, Daksh Kumar, Susant Katwal, Calvin R Wei, Neelum Ali

    This systematic review and meta-analysis compared the weight loss efficacy of tirzepatide versus semaglutide in overweight and obese adults through direct comparative studies. We systematically searched PubMed, Excerpta Medica database (EMBASE), Web of Science, and Cochrane Library databases from inception to April 25, 2025, identifying studies that directly compared tirzepatide and semaglutide for weight management. Inclusion criteria encompassed randomized controlled trials and observational studies reporting percentage change in body weight from baseline. Seven studies totaling 28,980 participants were included, comprising five observational studies and two randomized controlled trials with follow-up durations ranging from six to 12 months. Data analysis was performed using Review Manager 5.4.1 (The Cochrane Collaboration, London, UK) with random-effects models. Results demonstrated that tirzepatide was significantly superior to semaglutide in achieving weight reduction. The pooled analysis showed greater weight loss with tirzepatide compared to semaglutide (standardized mean difference: 0.75, 95% CI: 0.52 to 0.92). At six months, tirzepatide achieved significantly greater weight reduction than semaglutide (mean difference: 1.33, 95% CI: 0.58 to 2.08). Additionally, participants receiving tirzepatide had significantly higher odds of achieving at least 10% weight loss compared to those receiving semaglutide (OR: 0.21, 95% CI: 0.06 to 0.78). High heterogeneity was observed across studies (I² > 90%). This meta-analysis provides evidence that tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonist, demonstrates superior weight loss efficacy compared to semaglutide in overweight and obese populations. These findings support tirzepatide as a more effective pharmacological option for weight management, though further long-term head-to-head trials are needed to confirm sustained benefits and safety profiles.

    2025Cureus(2025)引用:3
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 565 篇论文

    合作机构(100)

    沙特国王大学合作论文 17
    All India Institute of Medical Sciences合作论文 16
    Institute of Medical Sciences,Banaras Hindu University合作论文 8
    Shimoga Institute of Medical Sciences合作论文 7
    克什米尔大学合作论文 7
    卡斯图尔巴医学院,马尼帕尔合作论文 7
    Khyber Medical University合作论文 5
    Khyber Girls Medical College合作论文 5
    拉合尔卫生科学大学合作论文 5
    Shalamar Medical and Dental College合作论文 5

    机构统计